Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics.
Doses of naloxone far below those which elicit emesis increase the sensitivity to motion sickness. In order to evaluate the possible interaction with broad spectrum antiemetics, low doses of naloxone were tested alone and in combination with 8-hydroxy-2-(di-n-propylamine)tetralin (DPAT), fentanyl and the NK1 antagonist CP-99994. A modified autonomic symptom rating scale was unaffected by any drug and thus considered of little value. Fentanyl and NK1 antagonists decreased the duration of the retch/vomit sequence. Naloxone alone and in combination with each of the drugs increased the duration of retching/vomiting. Naloxone also increased the number of vomiting sequences. The results are interpreted in terms of possible site(s) of action of the antiemetic drugs.
Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH, United States. Electronic address: james.lucot@wright.edu.
James B
JB
Lucot
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000008:administration & dosage; D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage*; D002415:Cats; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004639:Emetics / Q000008:administration & dosage*; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage; D023421:Models, Animal; D009041:Motion Sickness / Q000139:chemically induced*; D009270:Naloxone / Q000008:administration & dosage*; D064729:Neurokinin-1 Receptor Antagonists / Q000008:administration & dosage; D010812:Physical Stimulation; D010880:Piperidines / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced
D000932:Antiemetics; D004639:Emetics; D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D009270:Naloxone; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; D005283:Fentanyl
5-HT1A/1D; Cat; L-759274; Opioids